-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On March 9,, Bollinger Ingham announced in Shanghai that its new drug Pramipexole, Senfro, for the treatment of iexclusiveist Parkinson's disease symptoms and signs, had been approved for sale in ChinaThe drug is a selective non-baramine agonist that is used alone or in combination with levodopa throughout the entireofdiseasePraxo's chemical and receptor selectivity are different from bargos dopamine agonists such as Percot and Carmeprazole, and are very affinityive with dopamine D
2family receptors, including D
3and D
2receptorsSome researchers believe that the drug's binding to dopamine D
3receptors may be the biological basis for its antidepressant effectsA study called CALM-PD showed that in patients with early Parkinson's disease, using praxoas as an initial treatment significantly delayed the occurrence ofcomplications ofmovement, with significant differences from the levodopa group, where patients had good tolerance to the drugRecent studies have also shown that Plaxo can improve depressive symptoms and motivation in people with Parkinson's disease(reproduced from China Medical Daily)